Skip to main content
Subscribe
  • Sign Up Free
  • Login
  • Subscribe
  • News
    • Current News
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Digital Health
    • Transformation
    • ESG
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Opinion
    • Bold Moves
    • Breaking Bias
    • Commentaries
    • Letters
    • Vital Signs Blog
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top Innovators
    • Diversity in Healthcare
      • - Luminaries
      • - Top 25 Diversity Leaders
      • - Leaders to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Digital Health Transformation Summit
    • ESG: The Implementation Imperative Summit
    • Leadership Symposium
    • Social Determinants of Health Symposium
    • Women Leaders in Healthcare Conference
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Diversity Leaders Gala
    • Top 25 Women Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Hospital at Home
    • - Workplace of the Future
    • - Digital Health
    • - Future of Staffing
    • - Hospital of the Future (Fall)
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Video Series - The Check Up
    • Sponsored Video Series - One on One
  • Data Center
    • Data Center Home
    • Hospital Financials
    • Staffing & Compensation
    • Quality & Safety
    • Mergers & Acquisitions
    • Data Archive
    • Resource Guide: By the Numbers
    • Surveys
    • Data Points
  • Newsletters
  • MORE+
    • Contact Us
    • Advertise
    • Media Kit
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Technology
May 01, 2014 01:00 AM

Sovaldi costs less than other treatments

  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print

    Regarding “Reform Update: Medicaid plans look to states for help with expensive hepatitis C drug”:

    I acknowledge and appreciate the professionalism and objectivity in this article. I do take umbrage with the misrepresented financials surrounding Gilead's Sovaldi, a first-of-its-kind drug considered a cure for hepatitis C, rather than an approach at managing symptoms.

    The article says "they face massive outlays for the new hepatitis C drug Sovaldi, which costs $84,000 for a 12-week course of treatment."

    I agree that it is very unfortunate that government agencies are not making this drug available to everyone who needs it. I believe this article would have more leverage to bring change if it focused on how Sovaldi is a less expensive alternative, and therefore should immediately replace current treatment plans.

    An upfront cost of $84,000 for Sovaldi may look large to the average layperson, but I would caution that a professional institution has both a moral and professional obligation to present this cost in its proper context. Comparative analysis quite handily justifies the cost of the drug.

    According to Transplant Living, a single liver transplant costs an average of $577,000, including for pre- and post-op expenses. The $577,000 covers the cost of 6.87 Sovaldi treatments, which incidentally enjoy a higher success rate than a liver transplant. Further, Sovaldi has significantly higher availability than donated livers, and far fewer side effects compared to transplants.

    Of course, not every hep C patient receives a liver transplant. Many wait on a list for years while receiving management therapy, which has its own costs. Ongoing maintenance-type treatments end up costing more and more the longer the patient survives, in an essentially uncured state.

    Digressing from traditional treatment strategies, consider that according to one study, the expense of telaprevir-based triple therapy for hepatitis C—including adverse event management—is $189,000 per sustained viral response, or 2.25 times the price of Sovaldi.

    There are definite upsides to Sovaldi's quick treatment. I'll discuss a few. HCV is contagious. The sooner it is cured, the lower the risk of contagion. Chronic HCV can cause liver cancer. Having watched my father die from cancer that metastasized to his liver, I can identify with the financial and quality-of-life costs associated with this disease. A quick cure such as what Sovaldi offers will likely prevent the liver degradation, which then becomes a painful and costly cancer scenario. Finally, and this is more a tertiary cost, when a scarce commodity such as donated livers are not needed for HCV treatment, they can go to other patients.

    Lastly, there is a moral obligation to consider the patient's quality of life. In 12 weeks, one can be cured of hepatitis C forever, and resume enjoying life.

    Biotech companies such as Gilead spend years researching drugs, most of which never make it to market. When one drug does come to fruition, it has to carry the burden of all of the failures. I appreciate that this article does not make direct or implied slanders against Gilead. I would equally respect an initiative taken to explain to readers the drug cost in its true context, allowing an educated reader to make his own conclusions.

    F. Jason Harris

    Charleston, S.C.
    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    Chat-GPT-healthcare-2.png
    Why Boston Children's wants to hire a ChatGPT expert
    Screen Shot 2018-12-19 at 1.36.49 PM.png
    GE HealthCare stock drops despite revenue growth
    Most Popular
    1
    More healthcare organizations at risk of credit default, Moody's says
    2
    Centene fills out senior executive team with new president, COO
    3
    SCAN, CareOregon plan to merge into the HealthRight Group
    4
    Blue Cross Blue Shield of Michigan unveils big push that lets physicians take on risk, reap rewards
    5
    Bright Health weighs reverse stock split as delisting looms
    Sponsored Content
    Health IT Strategist (HITS) Newsletter: Sign up for the latest IT and medical technology news delivered 3 days a week (M, W, F).
     
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2023. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Digital Health
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • ESG
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Opinion
      • Bold Moves
      • Breaking Bias
      • Commentaries
      • Letters
      • Vital Signs Blog
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Excellence in Governance
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top Innovators
        • Diversity in Healthcare
          • - Luminaries
          • - Top 25 Diversity Leaders
          • - Leaders to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Conferences
        • Digital Health Transformation Summit
        • ESG: The Implementation Imperative Summit
        • Leadership Symposium
        • Social Determinants of Health Symposium
        • Women Leaders in Healthcare Conference
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Diversity Leaders Gala
        • Top 25 Women Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Hospital at Home
        • - Workplace of the Future
        • - Digital Health
        • - Future of Staffing
        • - Hospital of the Future (Fall)
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Video Series - The Check Up
      • Sponsored Video Series - One on One
    • Data Center
      • Data Center Home
      • Hospital Financials
      • Staffing & Compensation
      • Quality & Safety
      • Mergers & Acquisitions
      • Data Archive
      • Resource Guide: By the Numbers
      • Surveys
      • Data Points
    • Newsletters
    • MORE+
      • Contact Us
      • Advertise
      • Media Kit
      • Jobs
      • People on the Move
      • Reprints & Licensing